PRLD
Prelude Therapeutics Incorporated1.9900
+0.0500+2.58%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
125.10MP/E (TTM)
-Basic EPS (TTM)
-1.47Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Prelude Therapeutics posted Q3 revenue of $6.5M from its AbCellera deal, up from $3.0M y/y, yet narrowed its operating loss to $20.4M from $34.4M through 26% cuts in R&D and 34% in G&A, driven by lower stock-based comp and paused SMARCA2 trials. Net loss improved to $19.7M ($0.26/share) from $32.3M ($0.43/share), with EPS matching diluted shares at 76.1M. Cash fell to $58.2M amid $79.4M YTD operating burn, but Incyte's $60M infusion (November 2025) extends runway into 2027 despite program shifts. Cash burn slowed. Going concern doubts linger from funding needs.
8-K
Q3 loss narrows; cash to 2027
Prelude Therapeutics reported Q3 2025 net loss of $19.7M, down from $32.3M last year, with R&D expenses dropping to $21.7M amid pipeline progress. Cash stood at $58.2M, bolstered by AbCellera and $60M Incyte payments, funding operations into 2027. JAK2V617F inhibitor eyes IND in Q1 2026; KAT6A degrader mid-2026. ASH orals highlight both programs.
8-K
Prelude's Incyte option deal
Prelude Therapeutics inked an exclusive option deal with Incyte on November 3, 2025, granting Incyte rights to acquire its mutant selective JAK2V617F JH2 inhibitor program for MPN patients, yielding $35 million upfront cash and $25 million in equity. This bolsters Prelude's pipeline, prioritizing KAT6A degrader advancement into 2026 while pausing SMARCA2 clinical work to conserve resources. Leadership shifts as CMO Jane Huang exits, with Victor Sandor stepping in for oversight. Cash now funds operations into 2027.
8-K
Board appoints finance expert
Prelude Therapeutics announced the resignation of board member Mardi Dier, effective October 17, 2025, with no disagreements cited, and swiftly appointed Katina Dorton as her Class III successor and Audit Committee Chair. Dorton brings over 30 years in healthcare finance, including CFO roles at biotech firms and investment banking stints. This bolsters Prelude's governance amid pipeline advancement. Options for 76,000 shares vest over three years.
8-K
Nasdaq compliance regained
Prelude Therapeutics has regained compliance with Nasdaq's $1.00 minimum bid price requirement after its stock met the threshold. The notification arrived on September 18, 2025, closing the issue that arose from a March 27, 2025, deficiency notice. Compliance secured. This resolves prior delisting risks, stabilizing the company's market position without further action needed.
APRE
Aprea Therapeutics, Inc.
0.91-0.01
CNTX
Context Therapeutics Inc.
1.10-0.03
GLUE
Monte Rosa Therapeutics, Inc.
18.66+2.21
IDYA
IDEAYA Biosciences, Inc.
33.81+0.44
PHIO
Phio Pharmaceuticals Corp.
1.08-0.01
RLAY
Relay Therapeutics, Inc.
8.48+0.00
RNAZ
TransCode Therapeutics, Inc.
9.11+0.03
RPTX
Repare Therapeutics Inc.
2.23+0.03
SLXN
Silexion Therapeutics Corp
2.61+0.05
TNGX
Tango Therapeutics, Inc.
8.96-0.16